ClinicalTrialsFinder

RecruitingPhase 2NCT07113522

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)

Sponsor

Mirador Therapeutics, Inc.

Enrollment

140 participants

Start Date

Jun 26, 2025

Study Type

INTERVENTIONAL

Conditions

Crohn's Disease Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)

Summary

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2 study is evaluating new treatment combinations for people with moderate to severe Crohn's disease or ulcerative colitis — two chronic inflammatory bowel diseases. The study tests how well various investigational therapies work when added to or compared with current treatments. **You may be eligible if...** - For Crohn's disease: You have a confirmed diagnosis of Crohn's disease and have moderate to severe active disease based on standard clinical and endoscopic scoring - For ulcerative colitis: You have a confirmed diagnosis of UC with moderately to severely active disease based on a standard scoring system - Your current medications meet the study's stabilization requirements **You may NOT be eligible if...** - For Crohn's: You have indeterminate colitis, an active abscess, had extensive small bowel removed, or your disease involves only the stomach or upper intestine without colon/ileum involvement - For UC: You currently have or recently had a very severe flare (fulminant colitis, toxic megacolon), have a stoma, or have received intravenous steroids within 14 days Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMT-501

MT-501

DRUGMT-201

MT-201

Locations(66)

Mirador Therapeutics Selected Site

Birmingham, Alabama, United States

Mirador Therapeutics Selected Site

Scottsdale, Arizona, United States

Mirador Therapeutics Selected Site

Sun City, Arizona, United States

Mirador Therapeutics Selected Site

Little Rock, Arkansas, United States

Mirador Therapeutics Selected Site

Little Rock, Arkansas, United States

Mirador Therapeutics Selected Site

Colorado Springs, Colorado, United States

Mirador Therapeutics Selected Site

Littleton, Colorado, United States

Mirador Therapeutics Selected Site

Miami, Florida, United States

Mirador Therapeutics Selected Site

Miami, Florida, United States

Mirador Therapeutics Selected Site

Miami, Florida, United States

Mirador Therapeutics Selected Site

Orlando, Florida, United States

Mirador Therapeutics Selected Site

Palmetto Bay, Florida, United States

Mirador Therapeutics Selected Site

Pensacola, Florida, United States

Mirador Therapeutics Selected Site

Atlanta, Georgia, United States

Mirador Therapeutics Selected Site

Snellville, Georgia, United States

Mirador Therapeutics Selected Site

Glenview, Illinois, United States

Mirador Therapeutics Selected Site

Gurnee, Illinois, United States

Mirador Therapeutics Selected Site

Lafayette, Louisiana, United States

Mirador Therapeutics Selected Site

Marrero, Louisiana, United States

Mirador Therapeutics Selected Site

Shreveport, Louisiana, United States

Mirador Therapeutics Selected Site

Ypsilanti, Michigan, United States

Mirador Therapeutics Selected Site

Bridgeton, Missouri, United States

Mirador Therapeutics Selected Site

Kansas City, Missouri, United States

Mirador Therapeutics Selected Site

Liberty, Missouri, United States

Mirador Therapeutics Selected Site

Las Vegas, Nevada, United States

Mirador Therapeutics Selected Site

New York, New York, United States

Mirador Therapeutics Selected Site

Rochester, New York, United States

Mirador Therapeutics Selected Site

High Point, North Carolina, United States

Mirador Therapeutics Selected Site

Raleigh, North Carolina, United States

Mirador Therapeutics Selected Site

Cincinnati, Ohio, United States

Mirador Therapeutics Selected Site

Liberty Township, Ohio, United States

Mirador Therapeutics Selected Site

Providence, Rhode Island, United States

Mirador Therapeutics Selected Site

Greenville, South Carolina, United States

Mirador Therapeutics Selected Site

Cordova, Tennessee, United States

Mirador Therapeutics Selected Site

Dallas, Texas, United States

Mirador Therapeutics Selected Site

Garland, Texas, United States

Mirador Therapeutics Selected Site

Georgetown, Texas, United States

Mirador Therapeutics Selected Site

Houston, Texas, United States

Mirador Therapeutics Selected Site

Lubbock, Texas, United States

Mirador Therapeutics Selected Site

Southlake, Texas, United States

Mirador Therapeutics Selected Site

Tyler, Texas, United States

Mirador Therapeutics Selected Site

Webster, Texas, United States

Mirador Therapeutics Selected Site

Bellevue, Washington, United States

Mirador Therapeutics Selected Site

Silverdale, Washington, United States

Mirador Therapeutics Selected Site

Tacoma, Washington, United States

Mirador Therapeutics Selected Site

Milwaukee, Wisconsin, United States

Mirador Therapeutics Selected Site

Toronto, Canada

Mirador Therapeutics Selected Site

Kutaisi, Georgia

Mirador Therapeutics Selected Site

Marneuli, Georgia

Mirador Therapeutics Selected Site

Tbilisi, Georgia

Mirador Therapeutics Selected Site

Tbilisi, Georgia

Mirador Therapeutics Selected Site

Tbilisi, Georgia

Mirador Therapeutics Selected Site

Tbilisi, Georgia

Mirador Therapeutics Selected Site

Tbilisi, Georgia

Mirador Therapeutics Selected Site

Tbilisi, Georgia

Mirador Therapeutics Selected Site

Chisinau, Moldova

Mirador Therapeutics Selected Site

Chisinau, Moldova

Mirador Therapeutics Selected Site

Ivano-Frankivsk, Ukraine

Mirador Therapeutics Selected Site

Kyiv, Ukraine

Mirador Therapeutics Selected Site

Kyiv, Ukraine

Mirador Therapeutics Selected Site

Kyiv, Ukraine

Mirador Therapeutics Selected Site

Kyiv, Ukraine

Mirador Therapeutics Selected Site

Lutsk, Ukraine

Mirador Therapeutics Selected Site

Lviv, Ukraine

Mirador Therapeutics Selected Site

Poltava, Ukraine

Mirador Therapeutics Selected Site

Vinnytsia, Ukraine

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT07113522

Related Trials

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT0718494412 locations

Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

NCT073891611 location

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT0544256798 locations

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT031674371 location

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931196 locations